3 results about "Pre osteoblasts" patented technology

The invention belongs to the technical field of food-borne functional factors, and particularly relates to a bioactive glycopeptide as well as a preparation method and application thereof. According to the application, casein glycomacropeptide is taken as a substrate, specific protease is adopted for carrying out directional enzymolysis reaction on the casein glycomacropeptide, and after primary separation and purification by hydrophilic interaction chromatography and secondary purification by cation exchange chromatography are carried out, the bioactive glycopeptide with the molecular weight of less than 1,500 Da and more than 80% of components and the random coil secondary structure content of more than 35% is obtained. A system performance test shows that in an in-vitro cell experiment, the bioactive glycopeptide prepared by the embodiment of the invention can remarkably improve the proliferation rate of preosteoblasts and lay a sufficient cell quantity foundation for bone cell generation; meanwhile, the activity of an osteogenic early differentiation key marker ALP is effectively up-regulated, and the differentiation process of preosteoblasts towards the osteoblast direction is accelerated; in addition, the expression quantity of osteogenesis-related regulatory protein calcium-sensitive receptors is remarkably increased, and the function improvement of cells to mature bone cells is further promoted.

An injectable hydrogel for inhibiting osteosarcoma growth and its component preparation method are disclosed. The hydrogel is composed of curcumin nanoparticles, nano-hydroxyapatite, and methacryloxychitosan. This injectable hydrogel for inhibiting osteosarcoma growth combines the antitumor properties of curcumin nanoparticles, the osteogenic ability and good mechanical strength of nano-hydroxyapatite, and the porous structure and injectability of methacryloxychitosan. This injectable hydrogel for inhibiting osteosarcoma growth exhibits a significant killing effect on osteosarcoma cells and simultaneously promotes the proliferation of mouse embryonic pre-osteoblasts. Through its synergistic antitumor and osteogenic dual functions, this hydrogel shows promising application prospects in postoperative treatment of osteosarcoma.

The present invention relates to a novel lappaconitine derivative and a pharmaceutically acceptable salt thereof, a preparation method therefor, and a medical use thereof using osteogenesis-promoting activity. The lappaconitine derivative induces the differentiation of stem cells into preosteoblasts, and increases bone density when administered to an osteoporosis animal model, and induces osteogenesis, and thus can be effectively used for preventing, alleviating, or treating bone-related diseases such as osteoporosis.